Scopus Biopharma Inc (SCPS) Peer Comparison
$0.00
$-0.05
(-99.27%)
As on 27-Aug-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Edit
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
0 | 17,326 | 13,400 | 12,305 | 12,277 |
Revenue ($ Mln) |
-- | 2,782 | 2,436 | 670 | 1,664 |
Net Profit ($ Mln) |
-7.98 | 491.50 | 860.62 | -319.95 | 413.60 |
Net Margin (%) |
-- | 17.67 | 35.33 | -47.79 | 24.86 |
RoE (%) |
-- | 110.09 | 42.98 | -71.14 | 430.03 |
Price to Earnings |
-- | 36.49 | 17.01 | -- | 31.17 |
Price-To-Book |
2.42 | 39.43 | 7.27 | 26.44 | 83.92 |
Income Statement ($ Mln)
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 1,460.00 | 1,611.06 | 243.23 | 660.12 |
|
Cost of Revenue
|
0.00 | 1,027.56 | 57.91 | 10.42 | 139.30 |
|
Gross Profit
|
-- | 432.44 | 1,553.15 | 243.23 | 520.81 |
|
Operating Expenses
|
8.50 | 153.74 | 1,351.67 | 421.74 | 253.28 |
|
Operating Profit (EBIT)
|
-8.50 | 278.70 | 201.48 | -178.51 | 267.53 |
|
Other Income
|
0.00 | 7.07 | -0.20 | 0.77 | -1.67 |
|
Profit before Tax
|
-8.50 | 282.86 | 234.35 | -172.71 | 248.92 |
|
Provision for Tax
|
-0.11 | 37.49 | 52.07 | 3.79 | 46.79 |
|
Profit after Tax (Net Income)
|
-7.98 | 245.37 | 182.28 | -176.49 | 202.13 |
|
Minority Interest
|
0.54 | -- | -- | 19.82 | -- |
|
Consolidated Profit
|
-8.86 | 245.37 | 182.28 | -176.06 | 202.13 |
Liabilities ($ Mln)
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-9.45 | 386.39 | 2,488.43 | 398.52 | 169.80 |
|
Minority Interest
|
0.54 | -- | -- | 19.82 | -- |
|
Non-Current Liabilities
|
0.00 | 162.64 | 258.70 | 134.75 | 1,540.92 |
|
Current Liabilities
|
11.00 | 803.47 | 324.36 | 138.85 | 130.79 |
|
Total Liabilities
|
0.39 | 1,352.50 | 3,071.49 | 691.94 | 1,841.51 |
Assets ($ Mln)
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 1,018.53 | 1,452.73 | 286.64 | 1,102.50 |
|
Current Assets
|
0.50 | 333.96 | 1,618.76 | 405.30 | 739.01 |
|
Total Assets
|
0.39 | 1,352.50 | 3,071.49 | 691.94 | 1,841.51 |
|
Total Debt*
|
0.00 | 188.87 | 190.17 | 81.58 | 1,506.10 |
|
Net Current Assets
|
-10.51 | -469.51 | 1,294.40 | 302.30 | 608.22 |
Cashflow ($ Mln)
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-8.13 | 388.05 | 362.61 | -136.13 | 240.11 |
|
Cash Flow from Investing Activities
|
0.00 | -38.74 | -524.41 | -5.42 | -487.01 |
|
Cash from Financing Activities
|
0.24 | -775.78 | 0.59 | 65.19 | 362.37 |
|
Net Cash Inflow / Outflow
|
-- | -426.47 | -161.21 | -76.36 | 115.48 |
Ratios
Profitability Ratios
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
762.62 | 29.58 | 7.38 | -38.60 | 14.70 |
|
ROE (%)
|
762.62 | 36.64 | 7.76 | -43.72 | 110.23 |
|
ROA (%)
|
-86.03 | 16.29 | 6.41 | -25.18 | 13.72 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 16.73 | 11.32 | -72.33 | 30.70 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.28 | 0.12 | 0.76 | 0.49 |
|
EBIT Growth (%)
|
51.84 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
55.08 | 34.93 | -21.11 | -25.31 | -49.81 |
|
EPS Growth (%)
|
0.54 | 0.57 | -0.21 | -0.24 | -0.48 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.18 | 28.07 | 28.45 | -19.80 | 39.02 |
|
Price / Book Value
|
-0.29 | 17.82 | 2.08 | 8.77 | 46.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.17 | 22.87 | 18.29 | -19.04 | 28.62 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.49 | 0.08 | 0.20 | 8.87 |
|
Short term debt to equity ratio
|
0.00 | 0.13 | 0.01 | 0.01 | 0.08 |
|
Current Ratio
|
0.05 | 0.42 | 4.99 | 2.92 | 5.65 |
|
Quick Ratio
|
0.05 | -- | 4.89 | 3.07 | 4.88 |
|
Interest Coverage
|
-- | 98.37 | 3.75 | -35.47 | 15.69 |
Operating Efficiency Ratios
| Scopus Biopharma Inc (SCPS) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 17.36 | 13.33 | 0.58 | 35.00 |
|
Asset Turnover
|
0.00 | 0.97 | 0.57 | 0.35 | 0.45 |
|
Receivable days
|
-- | 55.02 | 56.39 | 8.76 | 89.10 |
|
Inventory Days
|
-- | -- | 191.72 | -302.34 | 201.93 |
|
Payable days
|
-- | 10.44 | 179.52 | 215.99 | 25.22 |
|
Cash Conversion Cycle
|
-- | -- | 68.58 | -509.57 | 265.81 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
